One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk ...

Are there significant gains ahead for one (or both) of these innovative biotechs?

Learn how CRISPR ETFs provide access to the gene-editing revolution, offering investors a diversified approach without picking individual biotech stocks.

Researchers developed PRINCE, a small-molecule-controlled CRISPR system enabling precise, long-term regulation of gene editing.

Researchers at Cornell University have developed a safer and more precise way to study how genes function in living tissues by refining a recently developed CRISPR-based genetic technique in fruit ...

Researchers at Columbia University College of Dental Medicine have developed an exosome-based platform, "safeEXO-Cas," that significantly enhances the delivery of CRISPR/Cas9 genome editing components ...

A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child with a rare genetic disorder. Unlike earlier ...

Early CRISPR-based cholesterol therapy shows striking LDL reduction, but experts warn that safety, durability and off-target ...

PLC, a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces the commercial ...

It has also aggressively invested in gene editing, including its 2025 acquisition of cardiovascular disease gene-editing ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...